

DAFTAR PUSTAKA

- Amzulescu, M. S. *et al.* (2019) 'Myocardial strain imaging: Review of general principles, validation, and sources of discrepancies', *European Heart Journal Cardiovascular Imaging*, 20(6), pp. 605–619. doi: 10.1093/ehjci/jez041.
- Armenian, S. H., Lacchetti, C. and Lenihan, D. (2017) 'Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline summary', *Journal of Oncology Practice*, 13(4), pp. 270–275. doi: 10.1200/JOP.2016.018770.
- Badano, L. P. *et al.* (2020) 'How to do right ventricular strain', *European Heart Journal Cardiovascular Imaging*, 21(8), pp. 825–827. doi: 10.1093/ehjci/jeaa126.
- Blessberger, H. and Binder, T. (2010) 'Two dimensional speckle tracking echocardiography: Basic principles', *Heart*, 96(9), pp. 716–722. doi: 10.1136/hrt.2007.141002.
- Calleja, A. *et al.* (2015) 'Right Ventricular Dysfunction in Patients With Breast Cancer Experiencing Cardiotoxicity During Trastuzumab Therapy', *Journal of the American College of Cardiology*, 65(10), p. A940. doi: 10.1016/s0735-1097(15)60940-8.
- Cardinale Daniela, D. and Sandri, M. T. (2010) 'Role of biomarkers in chemotherapy-induced cardiotoxicity', *Progress in Cardiovascular Diseases*, 53(2), pp. 121–129. doi: 10.1016/j.pcad.2010.04.002.
- Chang, W. T. *et al.* (2016) 'The early predictive value of right ventricular strain in epirubicin-induced cardiotoxicity in patients with breast cancer', *Acta Cardiologica Sinica*, 32(5), pp. 550–559. doi: 10.6515/ACS20151023A.
- Cherata, D. A. *et al.* (2019) 'Longitudinal strain analysis allows the identification of subclinical deterioration of right ventricular function in patients with cancer therapy-related left ventricular dysfunction', *Discoveries*, 7(2), p. e94. doi: 10.15190/d.2019.7
- Chow, E. J. *et al.* (2015) 'Individual prediction of heart failure among childhood cancer survivors', *Journal of Clinical Oncology*, 33(5), pp. 394–402. doi: 10.1200/JCO.2014.56.1373.
- Dhesi, S. *et al.* (2013) 'Cyclophosphamide-Induced Cardiomyopathy', *Journal of Investigative Medicine High Impact Case Reports*, 1(1),



p. 232470961348034. doi: 10.1177/2324709613480346.

- Esquivias, G. B. and Asteggiano, R. (2015) *Cardiac management of oncology patients: Clinical handbook for cardio-oncology*, *Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology*. doi: 10.1007/978-3-319-15808-2
- Ewer, M. S. and Lippman, S. M. (2005) 'Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity', *Journal of Clinical Oncology*, 23(13), pp. 2900–2902. doi: 10.1200/JCO.2005.05.827.
- Frey, M. K. and Bergler-Klein, J. (2021) 'Echocardiographic evaluation of patients undergoing cancer therapy', *European Heart Journal Cardiovascular Imaging*, 22(4), pp. 375–382. doi: 10.1093/ehjci/jeaa341.
- Geisberg, C. and Sawyer, D. B. (2010) 'Mechanism of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage', *Curr Hypertens Rep*, 12. doi: 10.1007/s11906-010-0146-y.Mechanisms.
- Haddad, F. *et al.* (2008) 'Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle', *Circulation*, 117(11), pp. 1436–1448. doi: 10.1161/CIRCULATIONAHA.107.653576.
- Hato, S. V. *et al.* (2014) 'Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics', *Clinical Cancer Research*, 20(11), pp. 2831–2837. doi: 10.1158/1078-0432.CCR-13-3141.
- Kadowaki, H. *et al.* (2020) 'Cancer Therapeutics-Related Cardiac Dysfunction — Insights from Bench and Bedside of Onco-Cardiology —', *Circulation Journal*, 84(9), pp. 1446–1453. doi: 10.1253/circj.CJ-20-0467.
- Kaklamani, V. G. and Gradishar, W. J. (2003) 'Epirubicin versus doxorubicin: Which is the anthracycline of choice for the treatment of breast cancer?', *Clinical Breast Cancer*, 4(SUPPL. 1), pp. 26–33. doi: 10.3816/CBC.2003.s.012.
- Keramida, K. *et al.* (2019) 'Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients', *European Journal of Heart Failure*, 21(4), pp. 529–535. doi: 10.1002/ejhf.1385.
- Lenneman, C. G. and Sawyer, D. B. (2016) 'Cardio-oncology: An update on cardiotoxicity of cancer-related treatment', *Circulation Research*, 118(6), pp. 1008–1020. doi: 10.1161/CIRCRESAHA.115.303633.

- Lyon, A. R. *et al.* (2022) '2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)', *European Heart Journal*, 43(41), pp. 4229–4361. doi: 10.1093/eurheartj/ehac244.
- Perez, I. E. *et al.* (2019) 'Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician', *Clinical Medicine Insights: Cardiology*, 13. doi: 10.1177/1179546819866445.
- Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., Decara, J. M., *et al.* (2014) 'Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American society of echocardiography and the European association of cardiovascular imaging', *Journal of the American Society of Echocardiography*, 27(9), pp. 911–939. doi: 10.1016/j.echo.2014.07.012.
- Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., *et al.* (2014) 'Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging', *European Heart Journal Cardiovascular Imaging*, 15(10), pp. 1063–1093. doi: 10.1093/ehjci/jeu192.
- Planek, M. I. C. *et al.* (2020) 'Prediction of doxorubicin cardiotoxicity by early detection of subclinical right ventricular dysfunction', *Cardio-Oncology*, 6(1), pp. 4–11. doi: 10.1186/s40959-020-00066-8.
- Sawyer, D. B. *et al.* (2010) 'Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection?', *Progress in Cardiovascular Diseases*, 53(2), pp. 105–113. doi: 10.1016/j.pcad.2010.06.007.
- Shiga, T. and Hiraide, M. (2020) 'Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines', *Current Treatment Options in Oncology*, 21(4). doi: 10.1007/s11864-020-0719-1.
- Suter, T. M. and Ewer, M. S. (2013) 'Cancer drugs and the heart: Importance and management', *European Heart Journal*, 34(15), pp. 1102–1111. doi: 10.1093/eurheartj/ehs181.

- Tanindi, A. *et al.* (2011) 'Assessment of right ventricular functions during cancer chemotherapy', *European Journal of Echocardiography*, 12(11), pp. 834–840. doi: 10.1093/ejechocard/jer142.
- Tim Riskesdas (2019) 'Laporan Nasional Riskesdas 2018', *Badan Penelitian dan Pengembangan Kesehatan*, p. 198. Available at: http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf.
- World Heart Organization (2020) 'Cancer Incident In The World', *WHO*.
- Xu, H. *et al.* (2021) 'Assessment of subclinical deterioration of right ventricular function by three-dimensional speckle tracking echocardiography in breast cancer patients undergoing anthracycline-based chemotherapy', *International Journal of General Medicine*, 14, pp. 885–893. doi: 10.2147/IJGM.S300257.
- Zamorano, J. L. *et al.* (2016) '2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines', *European Heart Journal*, 37(36), pp. 2768–2801. doi: 10.1093/eurheartj/ehw211.
- Zeglinski, M. *et al.* (2011) 'Trastuzumab-induced cardiac dysfunction: A "dual-hit"', *Experimental and Clinical Cardiology*, 16(3), pp. 70–74.

Lampiran Persetujuan Etik

	<p>KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN RSPTN UNIVERSITAS HASANUDDIN RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR Sekretariat : Lantai 2 Gedung Laboratorium Terpadu JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245. Contact Person: dr. Agussalim Bukhari, M.Med.,PhD, SpGK TELP. : 081241850858, 0411 5780103, Fax : 0411-581431</p>	
---	---	---

REKOMENDASI PERSETUJUAN ETIK

Nomor : 223/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 17 Mei 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22040163	No Sponsor Protokol	
Peneliti Utama	dr. Fathlina	Sponsor	
Judul Peneliti	Penilaian Parameter Right Ventricle Free Wall Longitudinal Strain (RVFWLS) Pada Pasien yang Menjalani Kemoterapi		
No Versi Protokol	2	Tanggal Versi	12 Mei 2022
No Versi PSP	2	Tanggal Versi	12 Mei 2022
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 27 April 2022	Masa Berlaku 17 Mei 2022 sampai 17 Mei 2023	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran Data Hasil Penelitian

No	No Sample	Jenis Kelamin	Umur (Tahun)	Diagnosis	Obat Kemoterapi	RVFWLS Pre-kemoterapi	RVFWLS Post-kemoterapi
1	RVFWLS 1	P	36	CA MAMMAE D	Docetaxel, Herzemab	21	19.6
2	RVFWLS 2	P	56	CA MAMMAE	Brexel, Doxorubicin, Cisplatin	19.7	16.4
3	RVFWLS 3	P	45	CA MAMMAE	Paclitaxe, Epirubicin	28.7	28.7
4	RVFWLS 4	P	46	CA MAMMAE	Paclitaxe, Epirubicin, Cyclophosphamide	24.6	21.3
5	RVFWLS 5	P	47	CA MAMMAE	Brexel, Kemodoxin, Cisplatin	25.6	22
6	RVFWLS 6	P	47	ADENOCA RECTI	Irinotecan, 5fu	23.7	23.3
7	RVFWLS 7	P	56	CA MAMMAE	Brexel, Doxorubicin, Cisplatin	28	24.2
8	RVFWLS 8	P	59	CA MAMMAE	Herzemab	23	20.3

9	RVFWLS 9	L	48	LIMFOMA MALIGNA NON HODGKIN	Cyclophosphamide, Doxorubicin, Vinkristin	20	17
10	RVFWLS 10	P	41	CA MAMMAE	Paclitaxel, Epirubicin, Cyclophosphamide Ferron	19.6	7
11	RVFWLS 11	P	44	CA MAMMAE	Doxorubicin + Paclitaxel	20	13.7
12	RVFWLS 12	P	57	CA MAMMAE	Brexel, Doxorubicin, Cyclophosphamide	30.6	29
13	RVFWLS 13	P	45	CA MAMMAE	Brexel, Doxorubicin, Cyclophosphamide	23.3	21.3
14	RVFWLS 14	P	58	CA MAMMAE	Brexel, Cisplatin, Herzemab	20.3	9.3
15	RVFWLS 15	P	29	CA MAMMAE	Paclitaxel, Doxorubicin	29	20
16	RVFWLS 16	P	36	CA MAMMAE D	Paclitaxel, Carboplatin	21.6	20.3
17	RVFWLS 17	L	35	LIMFOMA MALIGNA NON HODGKIN	Doxorubicin, Cisplatin	29.6	29.6
18	RVFWLS 18	P	59	CA MAMMAE	Brexe, Doxorubicni, Cyclophospamide	31	24.7

19	RVFWLS 19	P	59	CA MAMMAE D	Paclitaxel, Epirubicin, Cyclophosphamide	24.7	23
20	RVFWLS 20	P	42	CA MAMMAE D	Doxorubicin, Paclitaxel	27	5
21	RVFWLS 21	P	55	CA MAMMAE	Docetaxel, Epirubicin	21.7	10
22	RVFWLS 22	P	50	CA MAMMAE	Paclitaxel, Epirubicin, Cyclophosphamide	21.7	19.3
23	RVFWLS 23	P	28	CA MAMMAE	Doxorubicin, Paclitaxel	21.7	11.7
24	RVFWLS 24	P	63	CA MAMMAE	Brexel, Epirubicin, Cyclophosphamide	24.7	10
25	RVFWLS 25	P	55	CA MAMMAE	Brexel, Doxorubici, Cyclophosphamide	17.7	17.7
26	RVFWLS 26	P	32	CA MAMMAE	Brexel, Epirubicin, Cyclophosphamide	20	17.3
27	RVFWLS 27	P	47	CA MAMMAE	Paclitaxel, Epirubicin, Cyclophosphamide	22.3	20
28	RVFWLS 28	P	42	Limfoma Maligna Hodgkin	Doxorubicin, Cysplatin, Bleomisin, Dacarbazine	20	12.7

29	RVFWLS 29	P	65	CA MAMMAE	Cyclophosphamide, epirubicin, 5-fu	23.7	22
30	RVFWLS 30	P	70	CA MAMMAE	Paclitaxel, Epirubicin, Cyclophosphamide	20	15.7
31	RVFWLS 31	P	43	Limfoma Maligna Non Hodgkin	Cyclophosphamide, doxorubicin, vinkristin, Mabthera	21	18.3
32	RVFWLS 32	P	45	CA MAMMAE	Paclitaxel, Epirubicin,	20.7	17.7
33	RVFWLS 33	P	63	CA MAMMAE	Paclitaxel, Epirubicin, Cyclophosphamide	24.3	18.3
34	RVFWLS 34	P	44	CA MAMMAE	Paclitaxel, Epirubicin, Cyclophosphamide	23	19.7